Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice

Cell Death and Disease

Volumn 3, Issue 12, 2012, Pages

  Masciopinto, F ^a   Di Pietro, N ^a   Corona, C ^a   Bomba, M ^a   Pipino, C ^a   Curcio, M ^b   Di Castelnuovo, A ^c   Ciavardelli, D ^a,d   Silvestri, E ^b   Canzoniero, L M T ^b   Sekler, I ^e   Pandolfi, Assunta ^a   Sensi, S L ^a,f  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

^c Research Laboratories   (Italy)

^d KORE UNIVERSITY OF ENNA   (Italy)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glucose metabolism; Insulin signaling; LDH; Mitochondrial complex activity; Neurodegeneration; Pioglitazone

Indexed keywords

CYTOCHROME C OXIDASE; GLUCOSE; LACTATE DEHYDROGENASE; PIOGLITAZONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); 2,4 THIAZOLIDINEDIONE DERIVATIVE; PRESENILIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BRAIN CORTEX; BRAIN MITOCHONDRION; COGNITION; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT TERM MEMORY; TREATMENT DURATION; TREATMENT OUTCOME; ALZHEIMER DISEASE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PSYCHOLOGICAL ASPECT; TIME; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; FEMALE; GLUCOSE; HUMANS; MALE; MICE; MICE, TRANSGENIC; PRESENILIN-1; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 84878361153     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.189     Document Type: Article

References (60)

1. Hoyer S. Senile dementia and Alzheimer's disease. Brain blood flow and metabolism. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10: 447-478. (Pubitemid 17172634)
2. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942.
3. Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004; 63: 1902-1907. (Pubitemid 39532388)
4. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-178. (Pubitemid 38229951)
5. Frolich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci 1999; 893: 290-293. (Pubitemid 30038089)
6. Recio-Pinto E, Lang FF, Ishii DN. Insulin and insulin-like growth factor II permit nerve growth factor binding and the neurite formation response in cultured human neuroblastoma cells. Proc Natl Acad Sci USA 1984; 81: 2562-2566.
7. Baskin DG, Porte D Jr., Guest K, Dorsa DM. Regional concentrations of insulin in the rat brain. Endocrinology 1983; 112: 898-903.
8. Zhao W, Chen H, Xu H, Moore E, Meiri N, Quon MJ et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 1999; 274: 34893-34902. (Pubitemid 129509536)
9. Das P, Parsons AD, Scarborough J, Hoffman J, Wilson J, Thompson RN et al. Electrophysiological and behavioral phenotype of insulin receptor defective mice. Physiol Behav 2005; 86: 287-296. (Pubitemid 41478829)
10. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008; 131(Pt 12): 3311-3334.
11. Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci 2009; 29: 6734-6751.
12. Craft S, Baker LD, Montine TJ, Minoshima S,Watson GS, Claxton A et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69: 29-38.
13. Ott V, Benedict C, Schultes B, Born J, Hallschmid M. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012; 14: 214-221.
14. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012; 9: 35-66.
15. Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD et al. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009; 150: 707-712.
16. Nicolakakis N, Hamel E. The nuclear receptor PPARgamma as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease. Front Aging Neurosci 2010; 2.
17. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008; 22: 246-260.
18. De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 2009; 106: 1971-1976.
19. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 2006; 103: 443-448. (Pubitemid 43122420)
20. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003; 23: 9796-9804. (Pubitemid 37371592)
21. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 2004; 63: 8-20. (Pubitemid 38887104)
22. Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA et al. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 2004; 286: E252-E260. (Pubitemid 38140317)
23. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006; 55: 120-127. (Pubitemid 43343306)
24. Elder GA, Gama Sosa MA, De Gasperi R, Dickstein DL, Hof PR. Presenilin transgenic mice as models of Alzheimer's disease. Brain Struct Funct 2010; 214: 127-143.
25. Auffret A, Gautheron V, Repici M, Kraftsik R, Mount HT, Mariani J et al. Age-dependent impairment of spine morphology and synaptic plasticity in hippocampal CA1 neurons of a presenilin 1 transgenic mouse model of Alzheimer's disease. J Neurosci 2009; 29: 10144-10152.
26. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39 : 409-421. (Pubitemid 36937044)
27. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005; 128(Pt 6): 1442-1453. (Pubitemid 40826196)
28. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60. (Pubitemid 14088970)
29. Mumby DG, Gaskin S, Glenn MJ, Schramek TE, Lehmann H. Hippocampal damage and exploratory preferences in rats: memory for objects, places, and contexts. Learn Mem 2002; 9: 49-57. (Pubitemid 34507491)
30. Dere E, Huston JP, De Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007; 31: 673-704. (Pubitemid 46670336)
31. Akkerman S, Blokland A, Reneerkens O, van Goethem NP, Bollen E, Gijselaers HJ et al. Object recognition testing: methodological considerations on exploration and discrimination measures. Behav Brain Res 2012; 232: 335-347.
32. Stefanko DP, Barrett RM, Ly AR, Reolon GK, Wood MA. Modulation of long-term memory for object recognition via HDAC inhibition. Proc Natl Acad Sci USA 2009; 106: 9447-9452.
33. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ et al. Differential expression and activation of a family of murine peroxisome proliferatoractivated receptors. Proc Natl Acad Sci USA 1994; 91: 7355-7359. (Pubitemid 24226862)
34. Mammucari C, Rizzuto R. Signaling pathways in mitochondrial dysfunction and aging. Mech Ageing Dev 2010; 131: 536-543.
35. Schagger H. Electrophoretic techniques for isolation and quantification of oxidative phosphorylation complexes from human tissues. Methods Enzymol 1996; 264: 555-566. (Pubitemid 26089337)
36. Wittig I, Schagger H. Features and applications of blue-native and clear-native electrophoresis. Proteomics 2008; 8: 3974-3990.
37. Schagger H, von Jagow G. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal Biochem 1991; 199: 223-231.
38. Krieg AF, Rosenblum LJ, Henry JB. Lactate dehydrogenase isoenzymes a comparison of pyruvate-to-lactate and lactate-to-pyruvate assays. Clin Chem 1967; 13: 196-203.
39. Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GI et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech 2010; 3 : 525-534.
40. Hsiao G, Chapman J, Ofrecio JM, Wilkes J, Resnik JL, Thapar D et al. Multi-tissue, selective PPARgamma modulation of insulin sensitivity and metabolic pathways in obese rats. Am J Physiol Endocrinol Metab 2011; 300: E164-E174.
41. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
42. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 2000; 77: S26-S30.
43. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain; e-pub ahead of print 17 February 2012.
44. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004; 53: 1052-1059. (Pubitemid 38436618)
45. Ghosh S, Patel N, Rahn D, McAllister J, Sadeghi S, Horwitz G et al. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol Pharmacol 2007; 71: 1695-1702. (Pubitemid 47010922)
46. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 2005; 120: 483-495. (Pubitemid 40269763)
47. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 1994; 91: 10625-10629. (Pubitemid 24329051)
48. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011; 144: 810-823.
49. Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003; 278: 5828-5836. (Pubitemid 36800829)
50. Nakamichi N, Kambe Y, Oikawa H, Ogura M, Takano K, Tamaki K et al. Protection by exogenous pyruvate through a mechanism related to monocarboxylate transporters against cell death induced by hydrogen peroxide in cultured rat cortical neurons. J Neurochem 2005; 93: 84-93. (Pubitemid 40463518)
51. Zeng J, Yang GY, Ying W, Kelly M, Hirai K, James TL et al. Pyruvate improves recovery after PARP-1-associated energy failure induced by oxidative stress in neonatal rat cerebrocortical slices. J Cereb Blood Flow Metab 2007; 27: 304-315. (Pubitemid 46148457)
52. Wang TA, Yu YV, Govindaiah G, Ye X, Artinian L, Coleman TP et al. Circadian rhythm of redox state regulates excitability in suprachiasmatic nucleus neurons. Science 2012; 337: 839-842.
53. Searcy JL, Phelps JT, Pancani T, Kadish I, Popovic J, Anderson KL et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis 2012; 30: 943-961.
54. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 2008; 28: 9287-9296.
55. Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Del Rio J, Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor downregulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009; 379: 406-410.
56. Norris SL, Carson S, Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr Diabetes Rev 2007; 3: 127-140. (Pubitemid 46773852)
57. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554. (Pubitemid 40923063)
58. Duran-Sandoval D, Thomas AC, Bailleul B, Fruchart JC, Staels B. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development]. Med Sci (Paris) 2003; 19: 819-825.
59. Rabol R, Boushel R, Almdal T, Hansen CN, Ploug T, Haugaard SB et al. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes Obes Metab 2010; 12 : 806-814.
60. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 1999; 5: 101-106. (Pubitemid 29051006)